

Santosh Kesari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8987222/publications.pdf>

Version: 2024-02-01

57
papers

2,090
citations

279798

23
h-index

243625

44
g-index

57
all docs

57
docs citations

57
times ranked

3889
citing authors

#	ARTICLE	IF	CITATIONS
1	Anomaly Detection Framework for Wearables Data: A Perspective Review on Data Concepts, Data Analysis Algorithms and Prospects. <i>Sensors</i> , 2022, 22, 756.	3.8	22
2	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	12.4	13
3	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	4
4	Breaking down the bloodâ€“brain barrier. <i>Neuro-Oncology</i> , 2021, 23, 6-6.	1.2	1
5	Small molecules inhibitors of the heterogeneous ribonuclear protein A18 (hnRNP A18): a regulator of protein translation and an immune checkpoint. <i>Nucleic Acids Research</i> , 2021, 49, 1235-1246.	14.5	10
6	Phase I dose-escalation, safety, and CNS pharmacokinetic study of dexanabinol in patients with brain cancer. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab006.	0.7	4
7	Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 2044-2046.	1.3	1
8	WNT Signaling as a Therapeutic Target for Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8428.	4.1	32
9	Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab142.	0.7	15
10	Allosteric inhibitor of β -catenin selectively targets oncogenic Wnt signaling in colon cancer. <i>Scientific Reports</i> , 2020, 10, 8096.	3.3	15
11	IRE1 \pm and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cells. <i>Scientific Reports</i> , 2020, 10, 8348.	3.3	13
12	Cellular thermal shift analysis for interrogation of CRISPR-assisted proteomic changes. <i>BioTechniques</i> , 2020, 68, 180-184.	1.8	4
13	Strategy and Technique of Endonasal Endoscopic Bony Decompression and Selective Tumor Removal in Symptomatic Skull Base Meningiomas of the Cavernous Sinus and Meckel's Cave. <i>World Neurosurgery</i> , 2019, 131, e12-e22.	1.3	12
14	<p>Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 1937-1952.	6.7	284
15	Pritumumab, the first therapeutic antibody for glioma patients. <i>Human Antibodies</i> , 2019, 26, 95-101.	1.5	16
16	Leptomeningeal Metastases. <i>Current Treatment Options in Oncology</i> , 2018, 19, 3.	3.0	20
17	Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic Therapy. <i>American Journal of Roentgenology</i> , 2018, 211, 1342-1347.	2.2	10
18	Antibody drug conjugates: Progress, pitfalls, and promises. <i>Human Antibodies</i> , 2018, 27, 53-62.	1.5	33

#	ARTICLE	IF	CITATIONS
19	Wnt pathway: a hallmark of drug discovery challenge. <i>Future Medicinal Chemistry</i> , 2018, 10, 1399-1403.	2.3	4
20	Cellular target engagement: a new paradigm in drug discovery. <i>Future Medicinal Chemistry</i> , 2018, 10, 1641-1644.	2.3	7
21	Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma. <i>American Journal of Neuroradiology</i> , 2017, 38, 882-889.	2.4	9
22	Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. <i>CNS Oncology</i> , 2017, 6, 185-193.	3.0	43
23	Cellular immunotherapy of cancer: an overview and future directions. <i>Immunotherapy</i> , 2017, 9, 589-606.	2.0	13
24	Xenon in the treatment of panic disorder: an open label study. <i>Journal of Translational Medicine</i> , 2017, 15, 137.	4.4	21
25	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	4.1	32
26	A novel small molecule inhibitor of p32 mitochondrial protein overexpressed in glioma. <i>Journal of Translational Medicine</i> , 2017, 15, 210.	4.4	23
27	IGF2 mRNA binding protein 3 (IMP3) promotes glioma cell migration by enhancing the translation of RELA/p65. <i>Oncotarget</i> , 2017, 8, 40469-40485.	1.8	30
28	A community affair in the tumor microenvironment. <i>Oncotarget</i> , 2017, 8, 106173-106174.	1.8	1
29	Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma. <i>Oncotarget</i> , 2017, 8, 22370-22384.	1.8	23
30	Brainstem Glioma in Adults. <i>Frontiers in Oncology</i> , 2016, 6, 180.	2.8	42
31	Further understanding of the pathology of glioma: implications for the clinic. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1055-1065.	2.8	32
32	A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. <i>Neuro-Oncology</i> , 2016, 18, 849-854.	1.2	45
33	Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. <i>Science Translational Medicine</i> , 2016, 8, 341ra75.	12.4	158
34	A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria. <i>Clinical Cancer Research</i> , 2016, 22, 1445-1458.	7.0	25
35	A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1146-1156.	1.2	197
36	Leptomeningeal metastasis in breast cancer - a systematic review. <i>Oncotarget</i> , 2016, 7, 3740-3747.	1.8	61

#	ARTICLE	IF	CITATIONS
37	Multi-platform molecular profiling of a large cohort of glioblastomas reveals potential therapeutic strategies. <i>Oncotarget</i> , 2016, 7, 21556-21569.	1.8	24
38	ATNT-19TUMOR TREATING FIELDS WITH CHEMOTHERAPY COMPARED TO CHEMOTHERAPY ALONE IN GLIOBLASTOMA PATIENTS AT FIRST RECURRENCE: A POST-HOC ANALYSIS OF THE EF-14 TRIAL. <i>Neuro-Oncology</i> , 2015, 17, v14.4-v14.	1.2	0
39	Effect of the JAK2/STAT3 inhibitor SAR317461 on human glioblastoma tumorspheres. <i>Journal of Translational Medicine</i> , 2015, 13, 269.	4.4	56
40	DDEL-17CSF PHARMACOKINETICS AND PHARMACODYNAMICS IN BRAIN CANCER PATIENTS ON HIGH-DOSE ERLOTINIB. <i>Neuro-Oncology</i> , 2015, 17, v77.1-v77.	1.2	0
41	ATPS-64PRECLINICAL STUDIES USING NATIVIS VOYAGER RFE SYSTEM, A NOVEL NON-INVASIVE, LOW ENERGY, NON-THERMAL, NON-IONIZING RADIOFREQUENCY ENERGY (RFE) DEVICE IN GLIOBLASTOMA MOUSE MODELS. <i>Neuro-Oncology</i> , 2015, 17, v32.2-v32.	1.2	0
42	Overcoming tumor immune evasion with an unique arbovirus. <i>Journal of Translational Medicine</i> , 2015, 13, 3.	4.4	3
43	Mitochondrial p32 is upregulated in Myc expressing brain cancers and mediates glutamine addiction. <i>Oncotarget</i> , 2015, 6, 1157-1170.	1.8	39
44	A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. <i>Oncotarget</i> , 2015, 6, 4527-4536.	1.8	85
45	Plexin-B2 promotes invasive growth of malignant glioma. <i>Oncotarget</i> , 2015, 6, 7293-7304.	1.8	55
46	Hyaluronan expression in primary and secondary brain tumors. <i>Annals of Translational Medicine</i> , 2015, 3, 80.	1.7	11
47	Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs. <i>Journal of Translational Medicine</i> , 2014, 12, 13.	4.4	87
48	The extrinsic coagulation cascade and tissue factor pathway inhibitor in macrophages: A potential therapeutic opportunity for atherosclerotic thrombosis. <i>Thrombosis Research</i> , 2014, 133, 657-666.	1.7	16
49	Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: a retrospective cohort study. <i>Journal of Neuro-Oncology</i> , 2014, 119, 361-368.	2.9	22
50	Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. <i>Cancer Cell International</i> , 2014, 14, 26.	4.1	152
51	In silico modeling predicts drug sensitivity of patient-derived cancer cells. <i>Journal of Translational Medicine</i> , 2014, 12, 128.	4.4	26
52	Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. <i>Journal of Controlled Release</i> , 2014, 183, 146-153.	9.9	45
53	Protein interaction discovery using parallel analysis of translated ORFs (PLATO). <i>Nature Biotechnology</i> , 2013, 31, 331-334.	17.5	52
54	High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models. <i>PLoS ONE</i> , 2013, 8, e56185.	2.5	25

#	ARTICLE	IF	CITATIONS
55	Neoplastic meningitis resulting from hematological malignancies: pharmacokinetic considerations and maximizing outcome. <i>Clinical Investigation</i> , 2011, 1, 1391-1402.	0.0	7
56	Isolated Loss of Hormonal Receptors in Leptomeningeal Metastasis From Estrogen Receptor- and Progesterone Receptor-Positive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, e200-e202.	1.6	8
57	Brain metastases. <i>Current Opinion in Neurology</i> , 2005, 18, 654-661.	3.6	102